474 related articles for article (PubMed ID: 18029550)
1. Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking.
Xu X; Sutak R; Richardson DR
Mol Pharmacol; 2008 Mar; 73(3):833-44. PubMed ID: 18029550
[TBL] [Abstract][Full Text] [Related]
2. Egr-1 mediates hypoxia-inducible transcription of the NDRG1 gene through an overlapping Egr-1/Sp1 binding site in the promoter.
Zhang P; Tchou-Wong KM; Costa M
Cancer Res; 2007 Oct; 67(19):9125-33. PubMed ID: 17909017
[TBL] [Abstract][Full Text] [Related]
3. Changed iron regulation in scrapie-infected neuroblastoma cells.
Fernaeus S; Hälldin J; Bedecs K; Land T
Brain Res Mol Brain Res; 2005 Feb; 133(2):266-73. PubMed ID: 15710243
[TBL] [Abstract][Full Text] [Related]
4. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity.
Minotti G; Cavaliere AF; Mordente A; Rossi M; Schiavello R; Zamparelli R; Possati G
J Clin Invest; 1995 Apr; 95(4):1595-605. PubMed ID: 7706466
[TBL] [Abstract][Full Text] [Related]
5. Changes in gene expression with iron loading and chelation in cardiac myocytes and non-myocytic fibroblasts.
Parkes JG; Liu Y; Sirna JB; Templeton DM
J Mol Cell Cardiol; 2000 Feb; 32(2):233-46. PubMed ID: 10722800
[TBL] [Abstract][Full Text] [Related]
6. Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin.
Hoke EM; Maylock CA; Shacter E
Free Radic Biol Med; 2005 Aug; 39(3):403-11. PubMed ID: 15993339
[TBL] [Abstract][Full Text] [Related]
7. Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease.
Reznichenko L; Amit T; Zheng H; Avramovich-Tirosh Y; Youdim MB; Weinreb O; Mandel S
J Neurochem; 2006 Apr; 97(2):527-36. PubMed ID: 16539659
[TBL] [Abstract][Full Text] [Related]
8. Persistent effects of doxorubicin on cardiac gene expression.
Boucek RJ; Miracle A; Anderson M; Engelman R; Atkinson J; Dodd DA
J Mol Cell Cardiol; 1999 Aug; 31(8):1435-46. PubMed ID: 10423342
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy.
Minotti G; Ronchi R; Salvatorelli E; Menna P; Cairo G
Cancer Res; 2001 Dec; 61(23):8422-8. PubMed ID: 11731422
[TBL] [Abstract][Full Text] [Related]
10. Effects of cell proliferation on the uptake of transferrin-bound iron by human hepatoma cells.
Lee AW; Oates PS; Trinder D
Hepatology; 2003 Oct; 38(4):967-77. PubMed ID: 14512884
[TBL] [Abstract][Full Text] [Related]
11. Molecular pharmacology of the interaction of anthracyclines with iron.
Xu X; Persson HL; Richardson DR
Mol Pharmacol; 2005 Aug; 68(2):261-71. PubMed ID: 15883202
[TBL] [Abstract][Full Text] [Related]
12. Iron deficiency can upregulate expression of transferrin receptor at both the mRNA and protein level.
Tong X; Kawabata H; Koeffler HP
Br J Haematol; 2002 Feb; 116(2):458-64. PubMed ID: 11841452
[TBL] [Abstract][Full Text] [Related]
13. 4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.
Menna P; Salvatorelli E; Minotti G
Chem Res Toxicol; 2009 Jun; 22(6):978-83. PubMed ID: 19397277
[TBL] [Abstract][Full Text] [Related]
14. Regulation of transferrin receptor 2 in human cancer cell lines.
Calzolari A; Finisguerra V; Oliviero I; Deaglio S; Mariani G; Malavasi F; Testa U
Blood Cells Mol Dis; 2009; 42(1):5-13. PubMed ID: 19019709
[TBL] [Abstract][Full Text] [Related]
15. Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway.
Kwok JC; Richardson DR
Mol Pharmacol; 2003 Apr; 63(4):849-61. PubMed ID: 12644586
[TBL] [Abstract][Full Text] [Related]
16. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
Chaston TB; Lovejoy DB; Watts RN; Richardson DR
Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
[TBL] [Abstract][Full Text] [Related]
17. Examination of the mechanism(s) involved in doxorubicin-mediated iron accumulation in ferritin: studies using metabolic inhibitors, protein synthesis inhibitors, and lysosomotropic agents.
Kwok JC; Richardson DR
Mol Pharmacol; 2004 Jan; 65(1):181-95. PubMed ID: 14722250
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of dopamine transporter by iron chelation in vitro is mediated by altered trafficking, not synthesis.
Wiesinger JA; Buwen JP; Cifelli CJ; Unger EL; Jones BC; Beard JL
J Neurochem; 2007 Jan; 100(1):167-79. PubMed ID: 17227437
[TBL] [Abstract][Full Text] [Related]
19. The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5'-untranslated region.
Venti A; Giordano T; Eder P; Bush AI; Lahiri DK; Greig NH; Rogers JT
Ann N Y Acad Sci; 2004 Dec; 1035():34-48. PubMed ID: 15681799
[TBL] [Abstract][Full Text] [Related]
20. Oxygen-dependent regulation of NDRG1 in human glioblastoma cells in vitro and in vivo.
Said HM; Stein S; Hagemann C; Polat B; Staab A; Anacker J; Schoemig B; Theobald M; Flentje M; Vordermark D
Oncol Rep; 2009 Jan; 21(1):237-46. PubMed ID: 19082468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
